Recent research has unveiled promising findings regarding medications primarily designed for weight loss, suggesting their potential in reducing alcohol cravings. Specifically, drugs known as glucagon-like peptide-1 (GLP-1) analogues, such as liraglutide and semaglutide, could decrease alcohol consumption by nearly two-thirds. This breakthrough presents a dual benefit for individuals struggling with obesity and alcohol use disorder.
Conducted by researchers at University College Dublin, the study was centered on the usage of GLP-1 medications. Traditionally used to manage obesity, these drugs have shown unexpected effects on alcohol consumption. In a clinical trial involving 262 adults with a body mass index (BMI) over 27 kg/m², participants were prescribed GLP-1 analogues to aid weight loss.
Over an average period of four months, the average alcohol intake among participants plummeted from 11.3 units per week to just 4.3 units — a staggering reduction of 62%. Among regular drinkers, the decrease was even more pronounced, dropping from 23.2 units per week to 7.8 units, equating to a reduction of 68%. Notably, none of the participants reported an increase in alcohol consumption during the study.
Although the exact mechanism remains under investigation, early findings suggest that GLP-1 analogues may target cravings for alcohol in subcortical regions of the brain, which operate below the level of conscious control. This could explain why patients describe the change in their drinking habits as feeling “effortless.”
Alcohol use disorder is a significant public health issue, responsible for approximately 2.6 million deaths annually — about 4.7% of global deaths. Current treatment strategies, including cognitive behavioural therapy (CBT) and other medications, often face high relapse rates, with 70% of patients reverting to previous drinking patterns within a year.
The potential of GLP-1 medications introduces a novel avenue for addiction treatment, harnessing their ability to effect behavioural changes alongside managing obesity. Professor Carel le Roux, who led the study, emphasized the urgency in exploring the beneficial impacts of GLP-1s beyond the realm of weight loss.
The findings from this study signify a noteworthy advancement in the treatment provision for two intertwined health issues: obesity and alcohol use disorder. As researchers continue to explore the implications and effectiveness of GLP-1 analogues, there is cautious optimism surrounding their role in not only fostering weight loss but also in reducing harmful drinking behaviours. This could pave the way for integrated treatment strategies that address both obesity and alcohol cravings concurrently, potentially transforming the lives of millions affected by these conditions.
-Raja Aditya
